NCT04364035 - Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2020

Primary Completion Date

October 3, 2022

Study Completion Date

December 16, 2022

Conditions

HIV/AIDS

Interventions

BIOLOGICAL

ChAdOx1.HTI

ChAdOx1.HTI at week 0 and week 12; Vaccine delivered as one 0. 5 mL IM injection

BIOLOGICAL

MVA.HTI

MVA.HTI at week 24 and week 36; Vaccine delivered as one 0. 5 mL IM injection

DRUG

GS-9620

GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets

BIOLOGICAL

Placebo

Saline placebo delivered as one 0. 5 mL IM injection

DRUG

Placebo Oral Tablet

Unit-dose placebo tablet delivered as two 3-mg placebo tablets

Trial Locations (9)

Hospital La Princesa, Madrid

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Universitario Ramon y Cajal, Madrid

Hospital Universitario La Paz, Madrid

IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona

Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Clinic de Barcelona, Barcelona

Hospital Universitario Vall d'Hebrón, Barcelona